Immunomodulator Assets definition

Immunomodulator Assets means Intellectual Property, technology and other assets of Seller relating to Immunomodulators, including without limitation the Immunomodulator Technology, the Immunomodulator IP Assets identified on Schedule 3.3 hereto, and all assets and technology listed on Schedule 1(b), and intangible assets listed on Schedule 3.4, whether tangible, intangible, real, personal, or mixed, and wherever located.

Examples of Immunomodulator Assets in a sentence

  • For those who missed the meeting, copies are being mailed.If missed you, please let me know.

  • In circumstances where the Claimant was refusing to contemplate how software would potentially enable him to overcome this difficulty, it was not reasonable for the Respondent to explore the role in further detail with the Claimant at any point before his dismissal.

  • You may give us information about you by filling in forms on this Website, uploading content to this Website and or by corresponding with us by phone, e-mail or otherwise.

  • Additional visual media will be developed to include an interactive website, coasters, pens, bathroom advertisements and social media ads.

  • At the Closing, as full payment for the transfer of the Immunomodulator Assets to Buyer, Buyer shall deliver to Seller the Warrant (the “Purchase Price”).

  • Schedule 3.4 to this Agreement is a complete and accurate list of all intangible assets, other than those specifically referred to elsewhere in this Agreement, relating to or included in the Immunomodulator Assets.

  • Seller shall not sell, lease or transfer any of the Immunomodulator Assets, subject any of the Immunomodulator Assets to any Encumbrance or grant any rights to or under any of the Immunomodulator IP Assets.

  • Consider a two federate case with a single publisher generating updates at 10 Hz and a single subscriber, if a second subscriber is added to the network the number of updates sent by the publisher is constant.

  • NASWA has a technical committee that keeps track of exactly this information.

  • Note: The Screening Service Contractor Declaration (available from CAD website) shall(v) be duly completed by the screening service contractor (if applicable) and submitted to RACSF.

Related to Immunomodulator Assets

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Qualified high-technology business means a business that is either of the following:

  • Gene Therapy means a product or service for the treatment or prevention of a disease that utilizes ex vivo or in vivo delivery (via viral or nonviral gene transfer methods or systems) of Genetic Material, including any cell incorporating Genetic Material.

  • Licensor Technology means the Licensor Patents and the Licensor Know-How.

  • Transferred Technology has the meaning set forth in Section 2.3(a).

  • Vaccine means a specially prepared antigen which, upon administration to a person, will result in immunity and, specifically for the purposes of this rule, shall mean influenza and pneumococcal vaccines.

  • Developed Technology means any Technology including, without limitation, any enhancements, substitutions or improvements to the Core Technology that is (a) discovered, developed or otherwise acquired by DURA pursuant to the terms of the Development Agreement or (b) otherwise acquired by or on behalf of Xxxxxx Corp. II during the term of the Development Agreement.

  • Third Party Technology means all Intellectual Property and products owned by third parties and licensed pursuant to Third Party Licenses.

  • distributed ledger technology means a database system in which—

  • Opioid antagonist means a drug that binds to opioid

  • Cannabis products means cannabis that has undergone a process whereby the plant material has been transformed into a concentrate, including, but not limited to, concentrated cannabis, or an edible or topical product containing cannabis or concentrated cannabis and other ingredients.

  • Clean coal technology means any technology, including technologies applied at the precombustion, combustion, or post combustion stage, at a new or existing facility which will achieve significant reductions in air emissions of sulfur dioxide or oxides of nitrogen associated with the utilization of coal in the generation of electricity, or process steam which was not in widespread use as of November 15, 1990.

  • Bioassay means the determination of kinds, quantities or concentrations and, in some cases, the locations of radioactive material in the human body, whether by direct measurement, in vivo counting, or by analysis and evaluation of materials excreted or removed from the human body. For purposes of these rules, “radiobioassay” is an equivalent term.

  • Diagnostic mammography means a method of screening that

  • Customer Technology means Customer's proprietary technology, including Customer's Internet operations design, content, software tools, hardware designs, algorithms, software (in source and object forms), user interface designs, architecture, class libraries, objects and documentation (both printed and electronic), know-how, trade secrets and any related intellectual property rights throughout the world (whether owned by Customer or licensed to Customer from a third party) and also including any derivatives, improvements, enhancements or extensions of Customer Technology conceived, reduced to practice, or developed during the term of this Agreement by Customer.

  • Collaboration Technology means the Collaboration Know-How and the Collaboration Patents.

  • Company Technology means all Technology used in or necessary for the conduct of the business of the Company or any of its Subsidiaries, or owned or held for use by the Company or any of its Subsidiaries.

  • Program Technology means Program Know-How and Program Patents.

  • Collaboration IP means Collaboration Know-How and Collaboration Patents.

  • Developed IP means any Intellectual Property Rights that are conceived or reduced to practice, or otherwise created or developed, by or on behalf of a Party, its Affiliates or sublicensees, alone or together with one or more Third Parties, during the Term in connection with the Development, Manufacture, or use of the Compound or any Product.

  • Technology means any and all technical information and/or materials, including, without limitation, ideas, techniques, designs, sketches, drawings, models, inventions, know-how, processes, apparatus, methods, equipment, algorithms, software programs, data, software source documents, other works of authorship, formulae and information concerning engineering, research, experimental work, development, design details and specifications.

  • Marijuana products means concentrated marijuana products and marijuana products that are comprised of marijuana and other ingredients and are intended for use or consumption, such as, but not limited to, edible products, ointments, and tinctures.

  • Marijuana product means marijuana as defined in 50-32-101 and marijuana-infused products

  • After-Acquired Intellectual Property has the meaning assigned to such term in Section 4.02(d).

  • Cannabis product means cannabis that has undergone a process whereby the plant material has been transformed into a concentrate, including, but not limited to, concentrated cannabis, or an edible or topical product containing cannabis or concentrated cannabis and other ingredients.